summary
Introduced
05/22/2018
05/22/2018
In Committee
05/22/2018
05/22/2018
Crossed Over
Passed
Dead
12/31/2018
12/31/2018
Introduced Session
115th Congress
Bill Summary
Assessing Barriers to Opioid Use Disorder Treatment Act This bill requires the Government Accountability Office to report on barriers to the provision of medication used to treat substance use disorders (e.g., buprenorphine) under Medicaid distribution models (e.g., provider purchasing, storage, and administration of medications).
AI Summary
This bill requires the Government Accountability Office (GAO) to study and report on the barriers and options for State Medicaid programs in the distribution of substance use disorder treatment medications, such as buprenorphine, naltrexone, and buprenorphine-naloxone combinations. The study will evaluate different distribution models, including provider purchasing, storage, and administration of medications, pharmacist dispensing, and ordering from specialty pharmacies, to understand the effects on Medicaid beneficiary access, program costs, and provider willingness to prescribe these treatments. The GAO is required to submit a report to Congress with the study results and recommendations for legislative and administrative action within 15 months of the bill's enactment.
Committee Categories
Budget and Finance
Sponsors (3)
Last Action
Read twice and referred to the Committee on Finance. (on 05/22/2018)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/115th-congress/senate-bill/2909/all-info |
| BillText | https://www.congress.gov/115/bills/s2909/BILLS-115s2909is.pdf |
| Bill | https://www.congress.gov/115/bills/s2909/BILLS-115s2909is.pdf.pdf |
Loading...